The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
In first-line NSCLC the drug beats chemo, and not Keytruda.
And the company might one day follow Galapagos into decentralised manufacturing.
